Exforge HCT (Amlodipine / Valsartan / Hydrochlorothiazide)
Triple combination antihypertensive for blood pressure control
Exforge HCT is a prescription combination medication containing three active ingredients — amlodipine (a calcium channel blocker), valsartan (an angiotensin II receptor blocker), and hydrochlorothiazide (a thiazide diuretic). It is used to treat high blood pressure (hypertension) in adults whose blood pressure is not adequately controlled by two-drug therapy. By combining three complementary mechanisms of action in a single tablet, Exforge HCT provides effective blood pressure reduction and improved treatment adherence.
Quick Facts
Key Takeaways
- Exforge HCT combines three blood pressure-lowering mechanisms in one tablet, providing greater efficacy than dual-drug therapy.
- It is indicated only for adults whose hypertension is not adequately controlled by two-drug combinations, not as initial therapy.
- The medication must not be used during pregnancy due to the risk of serious fetal harm from the valsartan component.
- Common side effects include dizziness, ankle swelling, and increased urination; electrolyte levels should be monitored regularly.
- Take the tablet at the same time each day, with or without food, and do not stop abruptly without medical advice.
What Is Exforge HCT and What Is It Used For?
Exforge HCT is manufactured by Novartis and belongs to a class of medications known as fixed-dose combination antihypertensives. It brings together three well-established blood pressure-lowering agents, each working through a different pharmacological mechanism, to achieve more effective blood pressure control than can be obtained with any single agent or dual combination alone.
Amlodipine is a long-acting dihydropyridine calcium channel blocker (CCB). It works by relaxing the smooth muscle cells in arterial walls, causing the blood vessels to dilate. This reduces peripheral vascular resistance, which in turn lowers blood pressure. Amlodipine has a slow onset and a long duration of action, providing consistent blood pressure reduction over a full 24-hour period. It is particularly effective in older patients and those with isolated systolic hypertension.
Valsartan is an angiotensin II receptor blocker (ARB). It blocks the binding of angiotensin II to the AT1 receptor, which prevents the potent vasoconstrictor effects of this hormone. By blocking angiotensin II, valsartan reduces vasoconstriction, decreases aldosterone secretion (thereby reducing sodium and water retention), and provides cardioprotective effects. ARBs are well tolerated and do not cause the dry cough commonly associated with ACE inhibitors.
Hydrochlorothiazide (HCTZ) is a thiazide diuretic that acts on the distal convoluted tubule of the kidney to inhibit sodium and chloride reabsorption. This promotes the excretion of excess water and sodium, reducing blood volume and, consequently, blood pressure. HCTZ also has mild vasodilatory effects with long-term use. It remains one of the most widely prescribed antihypertensive medications worldwide and is recommended as first-line therapy by the World Health Organization (WHO) and the European Society of Cardiology (ESC).
The combination of these three agents is synergistic. The calcium channel blocker-induced peripheral edema is partially offset by the diuretic effect of HCTZ. Meanwhile, the ARB component counteracts the reflex activation of the renin-angiotensin-aldosterone system (RAAS) that can occur with both calcium channel blockers and diuretics. This complementary interaction results in greater blood pressure reduction with fewer side effects compared to increasing the dose of any single component.
Approved Indications
Exforge HCT is indicated for the treatment of essential hypertension in adults as substitution therapy. Specifically, it is approved for patients whose blood pressure is adequately controlled with the three individual substances (amlodipine, valsartan, and hydrochlorothiazide) given concurrently at the same dose levels, or for patients whose blood pressure is not adequately controlled by any two of the following: amlodipine, valsartan, and hydrochlorothiazide.
According to the European Society of Cardiology/European Society of Hypertension (ESC/ESH) 2023 Guidelines for the Management of Arterial Hypertension, triple combination therapy should be considered when blood pressure targets are not achieved with a two-drug combination at optimal doses. The guidelines specifically recommend the combination of an ARB (or ACE inhibitor), a calcium channel blocker, and a thiazide/thiazide-like diuretic as the preferred triple combination.
What Should You Know Before Taking Exforge HCT?
Contraindications
Exforge HCT must not be used in the following situations:
- Pregnancy and breastfeeding: Valsartan can cause serious injury or death to the developing fetus. The drug should be discontinued immediately if pregnancy is detected.
- Hypersensitivity: Known allergy to amlodipine, valsartan, hydrochlorothiazide, other sulfonamide-derived drugs, other dihydropyridine derivatives, or any of the excipients.
- Severe hepatic impairment: Including biliary cirrhosis and cholestasis.
- Severe renal impairment: Glomerular filtration rate (GFR) below 30 mL/min/1.73 m², or anuria (inability to produce urine).
- Refractory hypokalemia, hyponatremia, hypercalcemia, or symptomatic hyperuricemia: Conditions that may be worsened by the diuretic component.
- Concomitant use with aliskiren: In patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m²), due to increased risk of hyperkalemia, hypotension, and renal failure.
- Severe aortic stenosis: Amlodipine should not be used in patients with hemodynamically significant aortic stenosis.
- Cardiogenic shock or unstable angina pectoris: Excluding Prinzmetal's angina.
Warnings and Precautions
Special care should be taken in the following situations. Discuss these with your healthcare provider before starting Exforge HCT:
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue Exforge HCT as soon as possible. Use of drugs acting on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Hypotension: Excessive blood pressure lowering may occur, particularly in patients with volume or sodium depletion (e.g., those receiving high-dose diuretics, on a salt-restricted diet, or experiencing diarrhea or vomiting). Volume and/or sodium depletion should be corrected before initiating therapy.
- Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia (low potassium), hyponatremia (low sodium), hypochloremic alkalosis, and hypomagnesemia. Regular monitoring of serum electrolytes is recommended, particularly during the first weeks of treatment.
- Renal function: Changes in renal function may occur, especially in patients with renal artery stenosis, chronic kidney disease, congestive heart failure, or volume depletion. Monitor serum creatinine and estimated GFR periodically.
- Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. Valsartan is largely eliminated by biliary excretion, and amlodipine is extensively metabolized by the liver.
- Diabetes mellitus: Hydrochlorothiazide may impair glucose tolerance. Dose adjustment of antidiabetic medications (including insulin) may be required.
- Uric acid and gout: HCTZ can raise serum uric acid levels, potentially precipitating gout attacks in susceptible individuals.
- Systemic lupus erythematosus (SLE): Thiazide diuretics have been reported to exacerbate or activate SLE.
- Photosensitivity: Cases of photosensitivity reactions have been reported with thiazide diuretics. If photosensitivity occurs, discontinue the drug. Sun protection measures are recommended.
- Acute angle-closure glaucoma: Hydrochlorothiazide is a sulfonamide and can cause an idiosyncratic reaction resulting in acute myopia and acute angle-closure glaucoma. Seek immediate medical attention if you experience sudden decreased vision or eye pain.
Pregnancy and Breastfeeding
Exforge HCT is absolutely contraindicated during pregnancy. The valsartan component acts on the renin-angiotensin system and can cause fetal renal dysfunction, oligohydramnios (reduced amniotic fluid), skull bone hypoplasia, and even fetal death when used during the second and third trimesters. Hydrochlorothiazide crosses the placenta and can cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Women of childbearing potential should use effective contraception while taking Exforge HCT. If pregnancy is planned or confirmed, the medication should be discontinued immediately and an alternative antihypertensive therapy started under medical supervision. According to ESC/ESH guidelines, methyldopa, labetalol, and nifedipine are considered safe alternatives for blood pressure management during pregnancy.
It is not recommended to use Exforge HCT while breastfeeding. Hydrochlorothiazide is excreted in human breast milk. It is unknown whether amlodipine or valsartan are excreted in human milk, but animal studies suggest they may be. Due to the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug.
How Does Exforge HCT Interact with Other Drugs?
Drug interactions are an important consideration with Exforge HCT because it contains three active ingredients, each with its own interaction profile. The combination means more potential interactions than with single-component medications. The following sections outline the most clinically significant interactions.
Major Interactions
| Drug / Class | Component | Effect | Recommendation |
|---|---|---|---|
| Lithium | Valsartan + HCTZ | Increased lithium levels leading to toxicity (nausea, tremor, kidney damage) | Avoid combination; if necessary, monitor lithium levels closely |
| ACE inhibitors (e.g., enalapril, ramipril) | Valsartan | Dual RAAS blockade increases risk of hyperkalemia, hypotension, and renal failure | Contraindicated, especially in diabetics or renal impairment |
| Aliskiren | Valsartan | Dual RAAS blockade with increased risk of adverse events | Contraindicated in diabetes or GFR <60; avoid in other patients |
| Potassium supplements / Potassium-sparing diuretics | Valsartan + HCTZ | Risk of hyperkalemia or unpredictable electrolyte shifts | Monitor potassium levels frequently if combination unavoidable |
| NSAIDs (ibuprofen, naproxen, diclofenac) | All three | Reduced antihypertensive effect; increased risk of renal impairment | Use the lowest NSAID dose for the shortest duration; monitor BP and renal function |
Other Notable Interactions
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Digoxin | HCTZ-induced hypokalemia can increase digoxin toxicity; amlodipine may increase digoxin levels | Monitor digoxin levels and potassium |
| Simvastatin | Amlodipine may increase simvastatin levels, raising risk of myopathy | Limit simvastatin dose to 20 mg/day when used with amlodipine |
| Cyclosporine / Tacrolimus | Amlodipine may increase cyclosporine/tacrolimus levels | Monitor drug levels and adjust dose accordingly |
| Rifampicin / St. John's Wort | CYP3A4 inducers may decrease amlodipine plasma levels | Monitor blood pressure; dose adjustment may be needed |
| Antidiabetic agents (insulin, metformin) | HCTZ may impair glucose tolerance, reducing efficacy of antidiabetics | Monitor blood glucose; adjust antidiabetic dose as needed |
| Other antihypertensives | Additive blood pressure lowering; increased risk of hypotension | Use with caution; monitor blood pressure closely |
| Alcohol | Enhanced blood pressure lowering; increased dizziness and orthostatic hypotension | Limit alcohol consumption |
| Corticosteroids, ACTH | Intensified electrolyte depletion, especially hypokalemia | Monitor electrolytes regularly |
This list is not exhaustive. Because Exforge HCT contains three active ingredients, the potential for interactions is broader than with monotherapy. Always inform your healthcare provider and pharmacist about all medications, supplements, and herbal products you are taking. Your pharmacist can perform a comprehensive interaction check before dispensing.
What Is the Correct Dosage of Exforge HCT?
Exforge HCT is not intended as initial therapy. Patients should first be dose-titrated with the individual components or dual combinations before switching to the appropriate fixed-dose combination. The dose of Exforge HCT should be individualized based on the patient's current therapy, blood pressure goals, and tolerability.
Adults
Standard Dosing
One tablet taken orally once daily. The tablet should be swallowed whole with water, with or without food. It is recommended to take the dose at the same time each day, preferably in the morning, as hydrochlorothiazide has a diuretic effect that may cause increased urination.
| Strength | Amlodipine | Valsartan | HCTZ | Typical Use |
|---|---|---|---|---|
| 5/160/12.5 mg | 5 mg | 160 mg | 12.5 mg | Starting strength; patients switching from dual therapy |
| 10/160/12.5 mg | 10 mg | 160 mg | 12.5 mg | Higher amlodipine dose needed |
| 5/160/25 mg | 5 mg | 160 mg | 25 mg | Higher diuretic dose needed |
| 10/160/25 mg | 10 mg | 160 mg | 25 mg | Higher amlodipine and diuretic dose |
| 10/320/25 mg | 10 mg | 320 mg | 25 mg | Maximum dose; resistant hypertension |
Children and Adolescents
Exforge HCT is not recommended for use in children and adolescents under 18 years of age. Safety and efficacy have not been established in pediatric populations for this fixed-dose triple combination. Children with hypertension are typically managed with monotherapy or, when necessary, carefully titrated dual-drug regimens under specialist care.
Elderly Patients
No initial dose adjustment is generally required for elderly patients. However, caution is advised when uptitrating the dose, particularly in patients over 75 years of age. Elderly patients are more susceptible to orthostatic hypotension (dizziness upon standing), electrolyte imbalances, and renal impairment. Blood pressure should be monitored closely, and renal function and electrolytes should be checked regularly. The lowest effective dose should be used.
Patients with Renal Impairment
No dose adjustment is needed for patients with mild to moderate renal impairment (GFR 30–90 mL/min/1.73 m²). However, monitoring of potassium, creatinine, and uric acid levels is recommended. Exforge HCT is contraindicated in patients with severe renal impairment (GFR < 30 mL/min/1.73 m²) or anuria, as the thiazide component becomes ineffective and may worsen renal function.
Missed Dose
Take the missed dose as soon as you remember. If it is close to the time for your next scheduled dose (within approximately 12 hours), skip the missed dose and take your next dose at the usual time. Do not take two doses at the same time or a double dose to make up for a forgotten one. If you frequently forget doses, consider using a pill organizer or setting a daily reminder alarm.
Overdose
An overdose of Exforge HCT may cause severe hypotension (dangerously low blood pressure), dizziness, fainting, electrolyte disturbances, and excessive diuresis. In case of suspected overdose, seek emergency medical attention immediately. Treatment is supportive and may include intravenous fluids, vasopressors, and monitoring of cardiac rhythm and electrolytes. Amlodipine has a long half-life, so effects may be prolonged. Valsartan and hydrochlorothiazide are not effectively removed by hemodialysis.
What Are the Side Effects of Exforge HCT?
Like all medicines, Exforge HCT can cause side effects, although not everybody gets them. The side effects listed below reflect the combined profile of all three active ingredients. Many of these effects are dose-dependent and may resolve over time as your body adjusts to the medication. The side effects are categorized below by their approximate frequency of occurrence based on clinical trial data and post-marketing surveillance.
Very Common
- Peripheral edema (swelling of ankles and feet) — primarily due to amlodipine
- Increased urination (polyuria) — due to hydrochlorothiazide
Common
- Dizziness and lightheadedness
- Headache
- Fatigue and drowsiness
- Upper respiratory tract infections (nasopharyngitis)
- Nausea
- Diarrhea
- Muscle cramps and muscle pain
- Back pain
- Hypokalemia (low potassium levels)
- Increased blood uric acid levels
- Flushing (sensation of warmth in the face)
- Orthostatic hypotension (dizziness when standing up)
Uncommon
- Palpitations and rapid heartbeat (tachycardia)
- Abdominal pain
- Constipation
- Dry mouth
- Paresthesia (tingling, numbness)
- Visual disturbances
- Vertigo (spinning sensation)
- Erectile dysfunction
- Joint pain (arthralgia)
- Hyponatremia (low sodium levels)
- Hypomagnesemia (low magnesium levels)
- Elevated blood glucose
- Elevated liver enzymes
- Rash and pruritus (itching)
- Photosensitivity (increased skin sensitivity to sunlight)
Rare
- Angioedema (swelling of face, lips, tongue, or throat — seek immediate medical attention)
- Severe hypotension with syncope (fainting)
- Acute renal failure
- Pancreatitis (severe abdominal pain)
- Hepatitis or jaundice
- Interstitial nephritis
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Blood disorders: agranulocytosis, thrombocytopenia, leukopenia
- Gingival hyperplasia (swollen gums — amlodipine)
- Acute angle-closure glaucoma (HCTZ)
- Choroidal effusion (HCTZ)
Contact your healthcare provider or seek emergency medical help immediately if you experience: swelling of the face, lips, tongue, or throat (angioedema); difficulty breathing; severe dizziness or fainting; chest pain; irregular heartbeat; severe abdominal pain; yellowing of the skin or eyes (jaundice); significantly reduced urine output; or severe skin reactions with blistering.
In clinical trials, the adverse event profile of Exforge HCT was generally consistent with the known profiles of each individual component. The incidence of peripheral edema was lower in patients receiving the triple combination compared to amlodipine/valsartan alone, likely due to the diuretic effect of hydrochlorothiazide. This is one of the therapeutic advantages of the combination.
Long-term use of hydrochlorothiazide has been associated with a slightly increased risk of non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma). This risk appears to be related to cumulative dose and UV exposure. Patients taking Exforge HCT long-term should protect their skin from excessive sun exposure and have regular dermatological examinations.
How Should You Store Exforge HCT?
Proper storage of medications is essential to maintain their effectiveness and safety. Exforge HCT should be stored under the following conditions:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
- Moisture: Store in the original blister packaging or container to protect from moisture. The hydrochlorothiazide component is particularly sensitive to humidity.
- Light: Protect from direct sunlight and excessive light exposure.
- Accessibility: Keep out of the sight and reach of children. A locked medicine cabinet is recommended.
- Expiration: Do not use after the expiration date printed on the package. The expiration date refers to the last day of that month.
Do not dispose of medications in wastewater or household waste. Return unused or expired medicines to your pharmacy for proper disposal. This helps protect the environment and prevents accidental ingestion.
What Does Exforge HCT Contain?
Active Ingredients
Each film-coated tablet contains:
- Amlodipine (as amlodipine besylate) — a dihydropyridine calcium channel blocker that relaxes blood vessels
- Valsartan — an angiotensin II receptor blocker (ARB) that prevents blood vessel constriction
- Hydrochlorothiazide (HCTZ) — a thiazide diuretic that promotes water and sodium excretion
Inactive Ingredients (Excipients)
The tablet core typically contains:
- Microcrystalline cellulose
- Crospovidone
- Colloidal anhydrous silica (silicon dioxide)
- Magnesium stearate
The film-coating contains:
- Hypromellose (hydroxypropyl methylcellulose)
- Titanium dioxide (E171)
- Macrogol (polyethylene glycol)
- Talc
- Iron oxide yellow (E172) and/or iron oxide red (E172) — depending on the tablet strength
Exforge HCT does not contain lactose, gluten, or sucrose. Hydrochlorothiazide is a sulfonamide derivative; patients with a known sulfonamide allergy may have cross-sensitivity. Discuss any known drug allergies with your healthcare provider before starting treatment.
Frequently Asked Questions About Exforge HCT
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Exforge HCT — Summary of Product Characteristics. Available at: www.ema.europa.eu.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
- World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021.
- Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–39.
- Destro M, Luckow A, Samber M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study. J Am Soc Hypertens. 2008;2(4):294–302.
- U.S. Food and Drug Administration (FDA). Exforge HCT Prescribing Information. Available at: www.fda.gov.
- British National Formulary (BNF). Amlodipine, Valsartan, and Hydrochlorothiazide monographs. Available at: bnf.nice.org.uk.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357.
Editorial Team
This article was reviewed by the iMedic Medical Review Board, an independent panel of board-certified physicians specializing in cardiology, internal medicine, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international guidelines from ESC, AHA, and WHO.
iMedic is committed to providing evidence-based, accessible medical information. Our content is free from commercial influence and pharmaceutical sponsorship. We follow strict editorial standards and regular content review cycles. Read our editorial policy.